Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis

Rheumatology International

Volumn 33, Issue 4, 2013, Pages 1031-1037

  Jude, Claudia ^a   Dejica, Doru ^a   Samasca, Gabriel ^a   Balacescu, Loredana ^b   Balacescu, Ovidiu ^b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

CXCL10; IL 12; Rheumatoid arthritis; Soluble CD163

Indexed keywords

AZATHIOPRINE; BIOCHEMICAL MARKER; CD163 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT SWELLING; LABORATORY TEST; MALE; MIDDLE AGED; MORNING STIFFNESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; VASCULITIS; YOUNG ADULT; BLOOD;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; FEMALE; HUMANS; INTERLEUKIN-12; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE;

EID: 84877795860     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2459-4     Document Type: Article

References (44)

1. Zwadlo G, Voegeli R, Osthoff KS, Sorg C (1987) A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol 55: 295-304
2. Radzun HJ, Kreipe H, Bodewadt S, Hansmann ML, Barth J, Parwaresch MR (1987) Ki-M8 monoclonal antibody reactive with an intracytoplasmic antigen of monocyte/macrophage lineage. 69: 1320-1327
3. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK et al. (2001) Identification of the hemoglobin scavenger receptor. Nature 409: 198-201
4. Moestrup SK, Moller HJ (2004) CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 36: 347-354
5. Onofre G, Kolackova M, Jankovicova K, Krejsek J (2009) Scavenger receptor CD163 and its biological functions. Acta Med (Hradec Kralove) 52: 57-61
6. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964
7. Mosser DM (2003) The many faces of macrophage activation. J Leukoc Biol 73: 209-212
8. Nielsen MJ, Moller HJ, Moestrup SK (2010) Hemoglobin and heme scavenger receptor. Antioxid Redox Signal 12: 261-273
9. Stein M, Keshav S, Harris N, Gordon S (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176: 287-292
10. Sulahian TH, Hogger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C et al (2000) Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 12:1312- 1321
11. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G (2000) Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol 67: 97-103
12. Fabriek BO, Dijkstra CD, Van Den Berg TK (2005) The macrophage scavenger receptor CD163. Immunobiology 210:153- 160
13. Graversen JH, Madsen M, Moestrup SK (2002) CD163: signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol 34: 309-314
14. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO et al (2004) Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis. Antiinflammatory monocyte-macropgage responses in vitro, in resolving skin blister in vivo, and after cardiopulmonary bypass surgery. Circ Res 23: 119-126
15. Soares MP, Marguti I, Cunha A, Larsen R (2009) Immunoregulatory effects of HO-1: how does it work? Curr Opin Pharmacol 9: 482-489
16. Schaer CA, Vallelian F, Imhof A, Schoedon G, Schaer DJ (2008) Heme carrier protein (HCP-1) spatially interact with the CD163 hemoglobin uptake pathway and is a target of inflammatory macrophage activation. J Leukoc Biol 83: 325-333
17. Bogdan C, Vodovotz Y, Nathan C (1991) Macrophage deactivation by interleukin 10. J Exp Med 174: 1549-1555
18. Droste A, Sorg C, Hogger P (1999) Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochim Biophys Res Commun 256:110- 113
19. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK (2002) Identification of the haemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99: 378-380
20. Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura R, Matsuda T et al (2002) Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 130: 156-161
21. Greisen SR, Moller HJ, Stengaard-Pedersen K, Hetland ML, Horslev-Petersen K et al (2011) Soluble macrophage-derived CD163 is a marker of disease activity and is a marker of disease activity and progression in early rheumatoid arthritis. Clin Exp Rheumatol 29: 689-692
22. Baeten D, Moller HJ, Delanghe J, De Moestrup SK, Keyeser F (2004) Association of CD163 + macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylartropathy synovitis. Arthritis Rheum 50: 1611-1623
23. Nakayama W, Jinin M, Makino K, Kajihara I, Makino T, Fukushima S et al. (2010) Serum level of soluble CD163 in patients with systemic sclerosis. Rheumatol Int Dec 1
24. Arnett FC, Edworthy SM, Bloch DA, Mc Shane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324
25. Zwadlo-Klarwasser G, Bent S, Haubeck HD, Sorg C, Schmutzler W (1990) Glucocorticoid-induced appearance of the macrophage RM 3/1 in peripheral blood of man. Int Arch Allergy Appl Immunol 91: 175-180
26. Gerlag DM, Haringman JJ, Smeets TJM, Zwinderman AH, Kraan MC, Laud PJ et al (2004) Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 50: 3783-3791
27. Etzerodt A, Maniecki MB, Moller K, Moller JM, Moestrup SK (2010) Tumor necrosis factor alpha-converting enzyme (TACE/ ADAM 17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol 88: 1201-1205
28. Vandooren B, Noordenbos S, Ambarus C, Krausz S, Cantaert T, Yeremenko N et al (2009) Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 60: 966-975
29. Joosten LA, Lubberts E, Helsen MM, van den Berg WB (1997) Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J Immunol 159: 4094-4102
30. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Nat Cancer Inst 87: 557-561
31. Angiolillo AL, Sgadari C, Tosato G (1996) A role for the interferon- inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 795: 158-167
32. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G (1993) Interleukin-10 inhibits human lymphocyte IFN-gamma production by suppressing natural killer cell stimulatory factor/interleukin-12 synthesis in accessory cells. J Exp Med 178: 1041-1048
33. Hoewe MA, De Savage ND, Boer T, Langenberg DM, de Vaal Malefytss R, Ottenhoff TH, Verreck FA et al (2006) Divergent effects of IL-12 and IL-23 on production of IL-17 by human T cells. Eur J Immunol 36: 661-670
34. Kwak HB, Ha H, Kim HN, Lee JH, Kim HS, Lee S et al (2008) Reciprocal cross-talk between RANKL and interferon-gammainducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 58: 1332-1342
35. Szekanecz Z, Koch AE (2009) Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 51: 1-7
36. Fonseca JE, Edwards JCW, Blades S, Goulding NJ (2002) Macrophage subpopulation in rheumatoid synovium. Reduced CD163 expression in CD4 + T lymphocyte-rich microenvironments. Arthritis Rheum 46: 1210-1216
37. Davis BH, Zarev PV (2005) Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry Clin Cytometry 63: 16-22
38. Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA et al (2002) Endotoxin induces rapid metalloproteinasemediated shedding followed by upregulation of the monocyte hemeoglobin scavenger receptor CD163. J Leukoc Biol 72:711- 717
39. Weaver LK, Pioli PA, Wardwell K, Vogel SN, Guyre PM (2006) Up-regulation of human monocyte CD163 upon activation of cell-surface-Toll-like receptors. J Leukoc Biol 81: 663-671
40. Hogger P, Dreier J, Droste A, Buck F, Sorg C (1998) Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid- inducible member of the scavenger receptor cysteine rich family (CD163). J Immunol 161:1883- 1890
41. Timmermann M, Buck F, Sorg C, Hogger P (2004) Interaction of soluble CD163 with activated T lymphocytes involves its association with non-muscle myosin heavy chain type A. Immunol Cell Biol 82: 479-487
42. Frings W, Dreier J, Sorg C (2002) Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett 526: 93-96
43. Sulahian TH, Pioli PA, Wardwell K, Guyre PM (2004) Crosslinking of FcgammaR triggers shedding of the hemoglobin-haptoglobin scavenger receptor CD163. J Leukoc Biol 76: 271-277
44. Timmermann M, Hogger P (2005) Oxidative stress and 8-isoprostaglandin F (2 alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med 39: 98-107